Literature DB >> 8436181

The soluble interleukin-6 receptor is generated by shedding.

J Müllberg1, H Schooltink, T Stoyan, M Günther, L Graeve, G Buse, A Mackiewicz, P C Heinrich, S Rose-John.   

Abstract

The ligand-binding subunit (gp80) of the human interleukin-6 receptor (IL-6R) was transiently expressed in COS-7 cells. The metabolically labeled protein was shown to be quantitatively released from the membrane within 20 h. We identified the protein released from the transfected COS-7 cells after purification to homogeneity and N-terminal sequencing as a soluble form of the gp80/IL-6R. Shedding of the gp80 protein was strongly induced by 4 beta-phorbol-12-myristate-13-acetate, indicating that the process was regulated by protein kinase C (PKC). This was further corroborated by the finding that co-transfection of a PKC expression plasmid led to enhanced shedding of the gp80 protein. Since shedding of gp80 could not be prevented by treatment of the cells with inhibitors of all known classes of proteases, a novel protease seems to be involved. As a control, an unrelated membrane protein (vesicular stomatitis virus glycoprotein) was transfected into COS-7 cells and analyzed for shedding. Since the turnover of this protein was not mediated by shedding, we conclude that the release of gp80 from COS-7 cells is a specific process. The shed gp80 protein specifically binds IL-6, and this complex shows biological activity on human hepatoma cells. Human peripheral blood monocytes released a soluble form of the gp80 protein into the culture medium upon PMA treatment indicating that PKC-regulated shedding is the physiological mechanism of generation of the soluble IL-6R.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436181     DOI: 10.1002/eji.1830230226

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  127 in total

1.  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.

Authors:  J N Varghese; R L Moritz; M-Z Lou; A Van Donkelaar; H Ji; N Ivancic; K M Branson; N E Hall; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 2.  Interleukin-6 and insulin sensitivity: friend or foe?

Authors:  A L Carey; M A Febbraio
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

Review 3.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

4.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

5.  Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells.

Authors:  N Franchimont; S Rydziel; E Canalis
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

6.  Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; Sachi Kojima; Akiko Futakuchi; Tomokazu Fujimoto; Saori Sato-Ohira; Utako Tsutsumi; Hidenobu Tanihara
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

7.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

8.  The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.

Authors:  Paul Baran; Selina Hansen; Georg H Waetzig; Mohammad Akbarzadeh; Larissa Lamertz; Heinrich J Huber; M Reza Ahmadian; Jens M Moll; Jürgen Scheller
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

Review 9.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

10.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.